PMV Pharmaceuticals, Inc. Operating Income Loss

Quick Answer

PMV Pharmaceuticals, Inc. reported Operating Income Loss of -$86.21 million for the year ending 2025.

  • PMV Pharmaceuticals, Inc. showed a decrease of -0.9% in Operating Income Loss from 2024 to 2025.
  • This data is from PMV Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), PMV Pharmaceuticals, Inc.'s Operating Income Loss has declined by 356.3%.
  • Historical annual values: Fiscal year 2025: -$86.21 million | Fiscal year 2024: -$85.45 million | Fiscal year 2023: -$80.13 million | Fiscal year 2022: -$77.04 million | Fiscal year 2021: -$58.29 million | Fiscal year 2020: -$34.94 million | Fiscal year 2019: -$26.64 million | Fiscal year 2018: -$18.89 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: